Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial. However, ‘real-world’ data on this combination are limited. The ANASTASE stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paolo, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491680/
https://www.ncbi.nlm.nih.gov/pubmed/37684252
http://dx.doi.org/10.1038/s41523-023-00579-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491680/
https://www.ncbi.nlm.nih.gov/pubmed/37684252
http://dx.doi.org/10.1038/s41523-023-00579-2

Ejemplares similares